Stock Research for GRFS

GRFS

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

GRFS Stock Chart & Research Data

The GRFS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GRFS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


GRFS Due diligence Resources & Stock Charts

The GRFS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GRFS Detailed Price Forecast - CNN Money CNN View GRFS Detailed Summary - Google Finance
Yahoo View GRFS Detailed Summary - Yahoo! Finance Zacks View GRFS Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View GRFS Trends & Analysis - Trade-Ideas Barrons View GRFS Major Holders - Barrons
NASDAQ View GRFS Call Transcripts - NASDAQ Seeking View GRFS Breaking News & Analysis - Seeking Alpha
Spotlight View GRFS Annual Report - CompanySpotlight.com OTC Report View GRFS OTC Short Report - OTCShortReport.com
TradeKing View GRFS Fundamentals - TradeKing Charts View GRFS SEC Filings - Bar Chart
WSJ View Historical Prices for GRFS - The WSJ Morningstar View Performance/Total Return for GRFS - Morningstar
MarketWatch View the Analyst Estimates for GRFS - MarketWatch CNBC View the Earnings History for GRFS - CNBC
StockMarketWatch View the GRFS Earnings - StockMarketWatch MacroAxis View GRFS Buy or Sell Recommendations - MacroAxis
Bullish View the GRFS Bullish Patterns - American Bulls Short Pains View GRFS Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View GRFS Stock Mentions - StockTwits PennyStocks View GRFS Stock Mentions - PennyStockTweets
Twitter View GRFS Stock Mentions - Twitter Invest Hub View GRFS Investment Forum News - Investor Hub
Yahoo View GRFS Stock Mentions - Yahoo! Message Board Seeking Alpha View GRFS Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for GRFS - SECform4.com Insider Cow View Insider Transactions for GRFS - Insider Cow
CNBC View GRFS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GRFS - OTC Markets
Yahoo View Insider Transactions for GRFS - Yahoo! Finance NASDAQ View Institutional Holdings for GRFS - NASDAQ


Stock Charts

FinViz View GRFS Stock Insight & Charts - FinViz.com StockCharts View GRFS Investment Charts - StockCharts.com
BarChart View GRFS Stock Overview & Charts - BarChart Trading View View GRFS User Generated Charts - Trading View




Latest Financial News for GRFS


Is Grifols, S.A. (GRFS) a Great Stock for Value Investors?
Posted on Monday September 17, 2018

Is Grifols, S.A. (GRFS) a great pick from the value investor's perspective right now? Read on to know more.


Who Owns Grifols SA (BME:GRF)?
Posted on Tuesday September 11, 2018

A look at the shareholders of Grifols SA (BME:GRF) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owningRead More...


Grifols: Just-approved medicine will only be manufactured in Clayton
Posted on Friday September 07, 2018

A just-approved medicine to protect those exposed to hepatitis A and measles validates both the hundreds of millions of dollars a company is funneling into a manufacturing site in Johnston County and a regional branding effort aimed at recruiting more pharma to North Carolina.


Grifols Achieves Key Milestone with FDA Approval of the New Consolidated Manufacturing Facility (CMF) for Production of Recombinant Proteins
Posted on Thursday August 16, 2018

Additional submissions to the FDA are planned to relocate the production of other licensed recombinant protein products. The transition is targeted for completion in mid-2019, pending the FDA approvals for the licensed antigens. Once the transition is complete, Grifols will have transferred 21 products to CMF.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.